The Federal Circuit recently issued Rule 36 judgments in two separate BPCIA cases: Genentech v. Amgen and Janssen v. Celltrion. In Genentech v. Amgen, the Federal Circuit affirmed the U.S. District Court for the District of Delaware’s denial of Genentech’s motion for a preliminary injunction to enjoin sales of Amgen’s Kanjinti (trastuzumab-anns) biosimilar product. In part one, Goodwin's IP Litigation lawyer Brian Drummond explores some of the unanswered questions raised in Genentech v. Amgen. Read the BioProcess Online byline here.